Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

Blood

Volumn 96, Issue 2, 2000, Pages 384-392

  Kunzmann, Volker ^a   Bauer, Eva ^a   Feurle, Juliane ^a   Weißinger, Florian ^a   Tony, Hans Peter ^a   Wilhelm, Martin ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GAMMA INTERFERON; IBANDRONIC ACID; INTERLEUKIN 2; PAMIDRONIC ACID; CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MULTIPLE MYELOMA; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; BONE MARROW CELL; CELL DIVISION; DRUG EFFECT; IMMUNOLOGY; KINETICS; LYMPHOCYTE ACTIVATION;

ALENDRONATE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BONE MARROW CELLS; CELL DIVISION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; KINETICS; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; PLASMA CELLS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0034660687     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.384.013k07_384_392     Document Type: Article

References (44)

1. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med. 1996; 334:488.
2. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma: MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;100:317.
3. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97: 2692.
4. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593.
5. Dhodapkar MV, Singh J, Mehta J, et al. Antimyeloma activity of pamidronate in vivo. Br J Haematol. 1998;103:530.
6. Sasaki A, Boyca BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995;55:3551.
7. Massaia M, Attisano C, Peola S, et al. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood. 1993;82:1787.
8. Peest D, Leo R, Deicher H. Tumor-directed cytotoxicity in multiple myeloma - the basis for an experimental treatment approach with interleukin 2. Stem Cells. 1995;2:72.
9. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995; 345:1016.
10. Haas W, Pereira P, Tonegawa S. Gamma/delta cells. Annu Rev Immunol. 1993;11:637.
11. Fisch P, Malkovsky M, Kovats S, et al. Recognition by human Vγ9/Vδ2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science. 1990;250:1269.
12. Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H. Vγ2Vδ2 TCR-dependent recognition of nonpeptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol. 1995;154:998.
13. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic nonpeptide antigens recognized by human γ/δ T cells. Nature. 1995;375:155.
14. Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science. 1994;264:267.
15. Burk MR, Mori L, De Libero G. Human Vγ9-Vδ2 cells are stimulated in a cross-reactive fashion by a variety of phospnorylated metabolites. Eur J Ilmmunol. 1995;25:2052.
16. Tanaka Y, Sano S, Nieves E, et al. Nonpeptide ligands for human γδ T cells. Proc Natl Acad Sci U S A. 1994;91:8175.
17. De Libero G. Sentinel function of broadly reactive human γδ T cells. Immunol Today. 1997;18:22.
18. Kunzmann V, Bauer E, Wilhelm M. γ/δ T-cell stimulation by pamidronate [letter]. N Engl J Med. 1999;340:737.
19. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR. Natural and synthetic nonpeptide antigens recognized by human γδ T cells. Nature. 1995;375:155.
20. Leyvraz S, Hess U, Flesch G, et al. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst. 1992;84:788.
21. Sato M, Grasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88:2095.
22. Wesch D, Marx S, Kabelitz D. Comparative analysis of αβ and γδ T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate. Eur J Immunol. 1997;27:952.
23. Bukowski JF, Morita CT, Band H, Brenner MB. Crucial role of TCR γ chain junctional region in prenyl pyrophosphate antigen recognition by γδ T cells. J Immunol. 1998;161:286.
24. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581.
25. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999;96:133.
26. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997;12:1358.
27. Sauty A, Pecherstorfer M, Zimmer Roth I, et al. Interleukin-6 and tumor necrosis factor a levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996;18:133.
28. Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61:386.
29. Pecherstorfer M, Hammerl B, Jilch R, Horn E, Ludwig H. Effects of the bisphosphonates pamidronate, clodronate and ibandronate on CD69, an early T-lymphocyte activation marker [abstract]. Proc ASCO. 1998;17:446a.
30. Burk MR, Carena I, Donda A, Mariani F, Mori L, De Libero G. Functional inactivation in the whole population of human Vγ9/Vδ2 T lymphocytes induced by a nonpeptidic antagonist. J Exp Med. 1997;185:91.
31. Wright A, Lee JE, Link MP, et al. Cytotoxic T lymphocytes specific for self-tumor immunoglobulin express T cell receptor delta chain. J Exp Med. 1989;169:1557.
32. Bensussan A, Lagabrielle JF, Castaigne S, et al. Human CD3 γδ+ activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells. Nouv Rev Fr Hematol. 1989;31:129.
33. Duval M, Yotnda P, Bensussan A, et al. Potential antileukemic effect of γδ T cells in acute lymphoblastic leukemia. Leukemia. 1995;9:863.
34. Lamb LS Jr, Henslee Downey PJ, Parrish RS, et al. Increased frequency of TCR γδ+ T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996; 5:503.
35. Blanchi A, Montacchini L, Barral P, et al. CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+ cells. Br J Haematol. 1995;90:625.
36. Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med. 1991; 325:1078.
37. Morita CT, Verma S, Aparicio P, Martinez C, Spits H, Brenner MB. Functionally distinct subsets of human γ/δ T cells. Eur J Immunol. 1991;21: 2999.
38. Portier M, Zhang XG, Caron E, Lu ZY, Bataille R, Klein B. γ-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood. 1993;81:3076.
39. Spets H, Georgii Hemming P, Siljason J, Nilsson K, Jemberg Wiklund H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-γ and interferon-α in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood. 1998;92:2914.
40. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br J Haematol. 1997;98:665.
41. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998;12:220.
42. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58:5294.
43. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol. 1998;27:38.
44. Savage A, Belson D. Vescio R, Lichtenstein A, Berenson R. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients [abstract]. Blood. 1996;88:105a.